Literature DB >> 12520625

Single- and multiple-dose pharmacokinetics of oral creatine.

Adam M Persky1, Markus Müller, Hartmut Derendorf, Maria Grant, Gayle A Brazeau, Günther Hochhaus.   

Abstract

Supplementation with exogenous creatine (Cr) has shown physiological benefits in humans, but little is known about the pharmacokinetics of Cr in humans. Six healthy males completed an open-label study consisting of a full pharmacokinetic analysis following a single oral dose of Cr monohydrate (71 mg kg-1) and at steady-state after 6 days of Cr administration (71 mg kg-1 qid). After the single oral dose, the clearance (CL/F) was 0.20 +/- 0.066 L h-1 kg-1, tmax was 1.9 +/- 0.88 hours, and Cmax = 102.1 +/- 11.2 mg h L-1. At steady-state, CL/F decreased to 0.12 +/- 0.016 L h-1 kg-1, tmax did not change, and Cmax increased to 162.2 +/- 30.0 mg L-1. Penetration (AUCMUSCLE/AUCPLASMA) of Cr into the interstitial muscle space, as determined by microdialysis, was 0.47 +/- 0.09 and 0.37 +/- 0.27 for the single dose and at steady-state, respectively. Plasma and muscle data were simultaneously fitted with a model incorporating a saturable absorption and first-order elimination process. In conclusion, repeated dosing of Cr caused a reduction in clearance that could result from saturation of the skeletal muscle pool of Cr.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12520625     DOI: 10.1177/0091270002239703

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  11 in total

1.  Pharmacokinetics of unbound linezolid in plasma and tissue interstitium of critically ill patients after multiple dosing using microdialysis.

Authors:  Cornelia Buerger; Nele Plock; Pejman Dehghanyar; Christian Joukhadar; Charlotte Kloft
Journal:  Antimicrob Agents Chemother       Date:  2006-07       Impact factor: 5.191

2.  pH-dependent stability of creatine ethyl ester: relevance to oral absorption.

Authors:  Brandon T Gufford; Edward L Ezell; Dennis H Robinson; Donald W Miller; Nicholas J Miller; Xiaochen Gu; Jonathan L Vennerstrom
Journal:  J Diet Suppl       Date:  2013-09

3.  Total body skeletal muscle mass: estimation by creatine (methyl-d3) dilution in humans.

Authors:  Richard V Clark; Ann C Walker; Robin L O'Connor-Semmes; Michael S Leonard; Ram R Miller; Stephen A Stimpson; Scott M Turner; Eric Ravussin; William T Cefalu; Marc K Hellerstein; William J Evans
Journal:  J Appl Physiol (1985)       Date:  2014-04-24

4.  Sex-specific antidepressant effects of dietary creatine with and without sub-acute fluoxetine in rats.

Authors:  Patricia J Allen; Kristen E D'Anci; Robin B Kanarek; Perry F Renshaw
Journal:  Pharmacol Biochem Behav       Date:  2012-03-10       Impact factor: 3.533

Review 5.  Creatine for treating muscle disorders.

Authors:  Rudolf A Kley; Mark A Tarnopolsky; Matthias Vorgerd
Journal:  Cochrane Database Syst Rev       Date:  2013-06-05

Review 6.  Creatine metabolism and psychiatric disorders: Does creatine supplementation have therapeutic value?

Authors:  Patricia J Allen
Journal:  Neurosci Biobehav Rev       Date:  2012-03-24       Impact factor: 8.989

7.  Pilot investigation on long-term subcutaneous microdialysis: proof of principle in humans.

Authors:  Franziska Simmel; Claudia Kirbs; Zeynep Erdogan; Edith Lackner; Markus Zeitlinger; Charlotte Kloft
Journal:  AAPS J       Date:  2012-10-13       Impact factor: 4.009

8.  Creatine supplementation increases glucose oxidation and AMPK phosphorylation and reduces lactate production in L6 rat skeletal muscle cells.

Authors:  Rolando B Ceddia; Gary Sweeney
Journal:  J Physiol       Date:  2004-01-14       Impact factor: 5.182

Review 9.  A review of creatine supplementation in age-related diseases: more than a supplement for athletes.

Authors:  Rachel N Smith; Amruta S Agharkar; Eric B Gonzales
Journal:  F1000Res       Date:  2014-09-15

10.  Comparison of new forms of creatine in raising plasma creatine levels.

Authors:  Ralf Jäger; Roger C Harris; Martin Purpura; Marc Francaux
Journal:  J Int Soc Sports Nutr       Date:  2007-11-12       Impact factor: 5.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.